390
Participants
Start Date
September 30, 2025
Primary Completion Date
September 30, 2030
Study Completion Date
September 30, 2032
Gem/Nabpaclitaxel infusion
Downstaging and pathological response is empirically define as T1-2/N0/R0 status. If the anatomopathological analysis shows a lesion classified as T3-4 or N+ or R1, an adjuvant chemotherapy based on Gemcitabine with Nab Paclitaxel will be proposed for a period of 3 months.
mFOLFIRINOX infusion
Downstaging and pathological response is empirically define as T1-2/N0/R0 status. In that setting the patients will receive mFOLFIRINOX adjuvant chemotherapy 3 months.
CHU de Rouen, Rouen
Partenariat de Recherche en Oncologie DIGEstive - PRODIGE
UNKNOWN
Federation de recherche en chirurgie digestive (FRENCH)
UNKNOWN
University Hospital, Rouen
OTHER